LexThe PTAB environment has changed more in the past 18 months than in the preceding five years combined. Institution rates have fallen significantly. The discretionary denial framework has become more formalized and subject to increased Director-level oversight. New factors — domestic manufacturing presence, consistency of claim construction positions across forums, discretionary denial policy updates, Fintiv factors — now influence institution decisions in ways that would have seemed peripheral to the analysis not long ago.
Most practitioners are aware of these changes at a headline level. What's less common is a clear-eyed view of what they actually mean for strategy on both sides of a proceeding.
The most important number nobody is citing
The aggregate institution rate is the number that dominates discussions about the current PTAB environment. It has fallen sharply, and the direction of the trend is real and significant.
But the aggregate number is also one of the least useful statistics in PTAB practice right now — because the variance beneath it is so wide that the average tells you almost nothing about any specific case.
Institution rates for Bio/Pharma and Chemical patents have held up differently from rates for Electrical and Computer cases. The gap between these technology areas is substantial — wide enough that a practitioner whose entire practice is in high-tech electrical cases is operating in a fundamentally different PTAB environment than one who works primarily in bio/pharma, even though they are nominally subject to the same institution standards and the same Director's review.
The practitioners making the most informed decisions are the ones who know their specific technology area's institution history, not the aggregate.
The two-stage problem
The most important strategic insight about the current PTAB environment is that it has two distinct stages with very different dynamics — and most practitioners are conflating them.
The discretionary denial stage, where the Director decides whether to send a petition to a panel for merits review at all, is genuinely more restrictive than it has ever been. A significant proportion of petitions have been denied at this stage, many without detailed reasoning on the merits. This is real, and it requires a real response in how petitions are structured and timed.
But for petitions that survive this stage, merit institution rates remain close to historical norms. The prior art is still being taken seriously. Petitions that make it to panel review are still being instituted at strong rates.
The problem most petitioners are facing is therefore not that their prior art is weak or that PTAB panels have become hostile. The problem is that their petitions are being stopped before anyone evaluates the prior art — often for reasons related to the petitioner's claim construction or inconsistent positions taken in parallel district court litigation.
These are different problems requiring different solutions. A petition strategy optimized for the old environment — focused almost entirely on the quality of the prior art and the strength of the obviousness combination — may now fail for reasons that have nothing to do with those factors.
What the new factors actually require
The introduction of domestic manufacturing presence as a discretionary factor has received attention, but its practical implications are still being absorbed.
In substance, it changes the calculus for large technology companies with significant offshore manufacturing and for entities whose primary business is patent licensing rather than manufacturing. For these entities, the question of whether an IPR is even viable as a strategy now requires an explicit assessment of discretionary denial risk before investment in the merits build begins.
For patent owners, the shift has been more favorable than is often acknowledged. Challenged patents are surviving institution at higher rates. Licensing negotiations increasingly factor in the reduced administrative invalidation risk. A patent that might have been discounted for PTAB exposure two years ago looks different under the current framework.
The practitioners serving patent owner clients who have not updated their thinking about this shift are potentially leaving value on the table in negotiations and portfolio management decisions.
What preparation looks like now
The PTAB environment of 2026 rewards analytical work done earlier in the process than most petition strategies have traditionally required.
Understanding how the current discretionary denial framework has been applied across recent proceedings — by technology area, by petitioner profile, by patent age — is now foundational preparation, not supplementary research. Understanding whether the prior art search was scoped for the environment that existed two years ago or the one that exists today is a question worth asking before the petition is drafted.
On the patent owner side, understanding which patents in a portfolio have characteristics that make them more or less vulnerable under the current framework — and which validity challenge vehicles are most likely to be used against them — is portfolio intelligence that affects enforcement strategy, licensing positioning, and prosecution decisions for continuation applications.
The record of how the current framework has played out is available, growing, and increasingly informative. The practitioners building the habit of consulting it before committing to a strategy are better positioned than those still relying on intuitions formed in a different environment.
See the institution-rate variance for your technology area.
LexDana surfaces PTAB institution rates by art unit, tech center, and petitioner profile — cite-anchored to the Director's decisions and the underlying petitions.